VF
MREO

Virtu Financial’s Mereo BioPharma MREO Stock Holding History

Virtu Financial’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19K Buy
61,285
+24,827
+68% +$7.45K ﹤0.01% 1358
2026
Q1 		$12K Buy
+36,458
New +$15.6K ﹤0.01% 1444
2025
Q4 		– Sell
-15,970
Closed -$33K – 2023
2025
Q3 		$33K Buy
+15,970
New +$29.4K ﹤0.01% 1211
2024
Q3 		– Sell
-14,152
Closed -$51K – 1691
2024
Q2 		$51K Buy
+14,152
New +$45.8K ﹤0.01% 901
2024
Q1 		– Sell
-20,322
Closed -$47K – 1829
2023
Q4 		$47K Sell
20,322
-13,771
-40% -$26.3K ﹤0.01% 1183
2023
Q3 		$44K Buy
+34,093
New +$45.2K ﹤0.01% 923
2023
Q1 		– Sell
-19,745
Closed -$15K – 1864
2022
Q4 		$15K Sell
19,745
-14,135
-42% -$11.6K ﹤0.01% 1322
2022
Q3 		$29K Buy
+33,880
New +$41.5K ﹤0.01% 1326
2022
Q1 		– Sell
-63,045
Closed -$101K – 1819
2021
Q4 		$101K Buy
63,045
+50,843
+417% +$102K 0.01% 1131
2021
Q3 		$30K Buy
+12,202
New +$32.3K ﹤0.01% 1347
2021
Q1 		– Sell
-59,966
Closed -$215K – 1869
2020
Q4 		$215K Buy
+59,966
New +$150K 0.02% 814

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Virtu Financial's MREO Position: Q2 2026 in Review

Virtu Financial increased its Mereo BioPharma (MREO) stake by 68% in Q2 2026, buying an estimated $7.45K and bringing the position to 61,285 shares worth $19K. The position accounts for ﹤0.01% of the portfolio, ranked #1358.

Virtu Financial first reported a position in MREO in Q4 2020 and has held it in 11 quarters since. The position peaked at $215K in Q4 2020. 60 funds tracked by Wall St. Rank hold MREO as of Q2 2026.

  • Virtu Financial held 61,285 shares of Mereo BioPharma worth $19K as of Q2 2026.
  • Virtu Financial bought 24,827 Mereo BioPharma shares in Q2 2026, an estimated $7.45K.
  • Mereo BioPharma made up ﹤0.01% of Virtu Financial's portfolio in Q2 2026, its #1358 holding.
  • Virtu Financial first reported a position in Mereo BioPharma in Q4 2020 and has held it in 11 quarters since.
  • Virtu Financial's Mereo BioPharma position peaked at $215K in Q4 2020.
  • 60 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.